Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 6/20 | 0.36 |
| ▸ | CA1 | P00915 | 6/20 | 0.36 |
| ▸ | CA2 | P00918 | 6/20 | 0.36 |
| ▸ | CA7 | P43166 | 6/20 | 0.36 |
| ▸ | CA9 | Q16790 | 6/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035636 | 0.98 | LMNA (0.36) | LMNACHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL11229915 | 0.81 | NFKB1 (0.39) | CA12CA1CA2CA9CA14 | |
| SCHEMBL3205528 | 0.81 | ALDH1A1 (0.32) | TSHRALDH1A1 | |
| SCHEMBL1682242 | 0.81 | CA12 (0.43) | LMNACA12CA1CA2CA7 | |
| SCHEMBL47924 | 0.79 | CA12 (0.42) | LMNACA12CA1CA2CA7 | |
| SCHEMBL3110549 | 0.78 | SERPINE1 (0.37) | TDP1TSHR | |
| SCHEMBL28926409 | 0.78 | CHRM3 (0.33) | LMNACHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL8417905 | 0.78 | TSHR (0.35) | LMNACHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL8187265 | 0.78 | LMNA (0.44) | LMNACA1CA2TDP1KDM4E | |
| SCHEMBL47935 | 0.77 | ALDH1A1 (0.43) | LMNACHRM1TDP1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393552-B1 | A CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2017-12-20 | — | — | EP | claimed |
| US-9708292-B2 | Cyanopyrimidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-18 | — | — | US | claimed |
| EP-2253304-B1 | Nifedipine-based compositions for anti-wrinkle treatments | ANTROPOLI CARMINE (IT) | 2015-11-11 | — | — | EP | claimed |
| EP-2667897-A1 | PARABEN COMPOSITIONS | Anterios, Inc. (US) | 2013-12-04 | — | — | EP | claimed |
| US-20120321571-A1 | PARABEN COMPOSITIONS | ANTERIOS, INC. (US) | 2012-12-20 | — | — | US | claimed |
| WO-2012103040-A1 | PARABEN COMPOSITIONS | ANTERIOS, INC. (US) | 2012-08-02 | — | — | WO | claimed |
| US-20120022077-A1 | NOVEL CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | claimed |
| EP-2393552-A1 | A NOVEL CYANOPYRIMIDINE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-12-14 | — | — | EP | claimed |
| EP-2253304-A2 | Nifedipine-based compositions for anti-wrinkle treatments | Antropoli, Carmine (IT) | 2010-11-24 | — | — | EP | claimed |
| WO-2010090299-A1 | A NOVEL CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | WO | claimed |
| EP-1558227-B1 | INJECTABLE 2,6-DIISOPROPYLPHENOL-CONTAINING ANESTHETIC COMPOSITION AND METHODS | DAEWON PHARM CO LTD (KR) | 2006-10-04 | — | — | EP | claimed |
| EP-1558227-A1 | INJECTABLE 2,6-DIISOPROPYLPHENOL-CONTAINING ANESTHETIC COMPOSITION AND METHODS | Centurion, Inc. (KR) | 2005-08-03 | — | — | EP | claimed |
| WO-2004032910-A1 | INJECTABLE 2,6-DIISOPROPYLPHENOL-CONTAINING ANESTHETIC COMPOSITION AND METHODS | CENTURION, INC. (KR) | 2004-04-22 | — | — | WO | claimed |
| US-20040067919-A1 | Injectable 2, 6-diisopropylphenol-containing anesthetic composition and methods | CENTURION INC. | 2004-04-08 | — | — | US | claimed |
| EP-0532465-B1 | Protein fraction for cosmetic and dermatological care of the skin | PENTAPHARM AG (CH) | 2002-07-10 | — | — | EP | claimed |
| US-6099990-A | MIXING A LIGNIN MATERIAL WITH A SODIUM SULFATE SALT, HEATING THE LIGNIN AND SALT | MOTOROLA, INC. (US) | 2000-08-08 | — | — | US | claimed |
| US-5637304-A | Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use | FLARER S.A. PHARMACEUTICAL FINE CHEMICALS (CH) | 1997-06-10 | — | — | US | claimed |
| US-5322839-A | Isolated from seeds of legumes | PENTAPHARM AG | 1994-06-21 | — | — | US | claimed |
| EP-0532465-A1 | Protein fraction for cosmetic and dermatological care of the skin | Pentapharm A.G. (CH) | 1993-03-17 | — | — | EP | claimed |
| US-4410546-A | 4-BUTYL-OR PENTYLCYCLOHEXANECARBOXYLIC ACID | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1983-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022077-A1 | NOVEL CYANOPYRIMIDINE DERIVATIVE | ADORA2A, ADORA1, ADORA3 | LMNA 4003/4885CHRM3 134/4885CHRM2 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.